Recently published data from a Phase III clinical trial (RA-BEAM; NCT01710358) showed that RA patients treated with JAK1 and JAK2 inhibitors achieved significantly higher pain relief than patients treated with a tumor necrosis factor blocker [10]. The gene discussed is JAK1; the disease is rheumatoid arthritis.